A Gasdermin D Agonist Triggers Pyroptosis and Antitumor Immunity

Major Finding: Agonism of gasdermin D (GSDMD) triggers pyroptosis in cancer cells and inhibits tumor growth.Concept: The efficacy of the GSDMD agonist, DMB, is dependent on tumor cell GSDMD expression and the immune response.Impact: The synergy and absence of toxicity with immunotherapy position DMB as a promising anticancer therapeutic.